Eagle Pharmaceuticals (NASDAQ:EGRX) Downgraded to Hold at Zacks Investment Research

Eagle Pharmaceuticals (NASDAQ:EGRX) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday, January 9th.

According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “

Other analysts also recently issued research reports about the company. Piper Jaffray Companies restated a “buy” rating and issued a $75.00 price target on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th. ValuEngine upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, December 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $75.00 target price (down from $81.00) on shares of Eagle Pharmaceuticals in a research note on Thursday, November 9th. Finally, Mizuho reiterated a “sell” rating and set a $37.00 target price on shares of Eagle Pharmaceuticals in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. Eagle Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $63.67.

Eagle Pharmaceuticals (NASDAQ:EGRX) opened at $58.37 on Tuesday. The company has a market capitalization of $886.79, a P/E ratio of 9.41 and a beta of 1.25. The company has a current ratio of 5.30, a quick ratio of 5.15 and a debt-to-equity ratio of 0.26. Eagle Pharmaceuticals has a 52-week low of $45.05 and a 52-week high of $97.15.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.50. Eagle Pharmaceuticals had a return on equity of 62.60% and a net margin of 36.95%. equities research analysts forecast that Eagle Pharmaceuticals will post 2.23 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Kopp Investment Advisors LLC raised its holdings in Eagle Pharmaceuticals by 0.3% during the second quarter. Kopp Investment Advisors LLC now owns 3,060 shares of the specialty pharmaceutical company’s stock valued at $241,000 after acquiring an additional 10 shares during the period. PNC Financial Services Group Inc. raised its holdings in Eagle Pharmaceuticals by 0.7% during the second quarter. PNC Financial Services Group Inc. now owns 11,269 shares of the specialty pharmaceutical company’s stock valued at $889,000 after acquiring an additional 82 shares during the period. D.A. Davidson & CO. raised its holdings in Eagle Pharmaceuticals by 2.4% during the second quarter. D.A. Davidson & CO. now owns 4,350 shares of the specialty pharmaceutical company’s stock valued at $343,000 after acquiring an additional 100 shares during the period. Bank of New York Mellon Corp raised its holdings in Eagle Pharmaceuticals by 0.4% during the second quarter. Bank of New York Mellon Corp now owns 116,510 shares of the specialty pharmaceutical company’s stock valued at $9,191,000 after acquiring an additional 482 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Eagle Pharmaceuticals by 3.9% during the second quarter. Legal & General Group Plc now owns 14,984 shares of the specialty pharmaceutical company’s stock valued at $1,182,000 after purchasing an additional 563 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Eagle Pharmaceuticals (NASDAQ:EGRX) Downgraded to Hold at Zacks Investment Research” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/04/zacks-investment-research-lowers-eagle-pharmaceuticals-egrx-to-hold.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply